Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis.
BACKGROUND
Recent studies suggest that lipids, including free fatty acids (FFAs), are necessary for proper μ opioid receptor (MOR) binding and that activation of opioid receptors (ORs) improves intestinal inflammation. The objective of the study was to investigate a possible interaction between the ORs and FFA receptors (FFARs) ligands in the colitis.


METHODS
The potential synergistic effect of ORs and FFARs ligands was evaluated using mouse model of acute colitis induced by dextran sulfate sodium (DSS, 4%). Compounds were injected intraperitoneally (i.p.) once or twice daily at the doses of 0.01 or 0.02 mg/kg body weight (BW) (DAMGO-an MOR agonist), 0.3 mg/kg BW (DPDPE-a δ OR (DOR) agonist) and 1 mg/kg BW (naloxone-a non-selective OR antagonist, GLPG 0974-a FFAR2 antagonist, GSK 137647-a FFAR4 agonist and AH 7614-a FFAR4 antagonist) for 4 days.


RESULTS
Myeloperoxidase (MPO) activity was significantly decreased after DAMGO (0.02 mg/kg BW) and GSK 137647 (1 mg/kg BW) administration and co-administration as compared to DSS group.


CONCLUSIONS
Treatment with ligands of ORs and FFARs may affect the immune cells in the inflammation; however, no significant influence on the severity of colitis and no synergistic effect were observed.
['Binienda|Agata|A|0000-0002-1173-2966', 'Makaro|Adam|A|0000-0002-0695-9808', 'Talar|Marcin|M|0000-0001-8685-1161', 'Krajewska|Julia B|JB|', 'Tarasiuk|Aleksandra|A|0000-0002-5306-3158', 'Bartoszek|Adrian|A|', 'Fabisiak|Adam|A|0000-0002-6997-4925', 'Mosińska|Paula|P|', 'Niewinna|Karolina|K|', 'Dziedziczak|Katarzyna|K|', 'Świerczyński|Mikołaj|M|', 'Kordek|Radzisław|R|', 'Salaga|Maciej|M|0000-0002-5917-8749', 'Fichna|Jakub|J|0000-0002-8443-4417']
free fatty acid receptors colitis lipids opioid receptor DAMGO